Detalhe da pesquisa
1.
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol;
178: 119-129, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37862791
2.
Homologous Recombination Deficiency: Concepts, Definitions, and Assays.
Oncologist;
27(3): 167-174, 2022 03 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35274707
3.
Small cell cancers of the female genital tract: Molecular and clinical aspects.
Gynecol Oncol;
149(2): 420-427, 2018 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29458976
4.
Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.
Mod Pathol;
29(1): 60-6, 2016 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26564006
5.
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
J Immunother Cancer;
12(1)2024 01 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38242717
6.
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119.
J Pathol Clin Res;
10(3): e12371, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38627977
7.
Validated gene targets associated with curatively treated advanced serous ovarian carcinoma.
Gynecol Oncol;
128(3): 512-7, 2013 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23168173
8.
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.
JCO Precis Oncol;
7: e2200317, 2023 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37099733
9.
The testis-specific factor CTCFL cooperates with the protein methyltransferase PRMT7 in H19 imprinting control region methylation.
PLoS Biol;
4(11): e355, 2006 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17048991
10.
Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers.
Nat Commun;
10(1): 4369, 2019 09 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31554806
11.
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.
Nat Commun;
10(1): 558, 2019 02 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30718512
12.
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade.
J Natl Cancer Inst;
110(7): 787-790, 2018 07 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29365144
13.
The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair.
Oncotarget;
8(8): 13792-13804, 2017 Feb 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28099152
14.
miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas.
Sci Rep;
7(1): 3614, 2017 06 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28620240
15.
Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type.
Am J Surg Pathol;
40(3): 395-403, 2016 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26645725
16.
New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair.
Mol Cancer Ther;
13(6): 1645-54, 2014 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24694947
17.
Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
Nat Genet;
46(5): 424-6, 2014 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24658004
18.
A novel mammalian complex containing Sin3B mitigates histone acetylation and RNA polymerase II progression within transcribed loci.
Mol Cell Biol;
31(1): 54-62, 2011 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21041482
19.
Sin3B expression is required for cellular senescence and is up-regulated upon oncogenic stress.
Cancer Res;
69(16): 6430-7, 2009 Aug 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19654306